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those with lab measures, results differed between those in remission vs. those who 
were not: mean ESR(mm/h): 18.9vs.37.2, mean CRP(mg/dl): 1.6vs.5.3, Rheumatoid 
Factor (% positive): 87%-vs-89%, Anti-CCP (% positive): 74%-vs-79% and HLA-B27 (% 
positive): 7%-vs-9%. Among those with data, recent (mean) disease severity scores 
differed between those in remission vs. those who were not: Tender Joint Count: 
1.6-vs-6.3, Swollen Joint Count: 0.8-vs-4.8, 100mm VAS score: 18.9-vs-39.8, HAQ: 
0.6-vs-1.5 and DAS28: 2.2-vs-4.1. ConClusions: More than half of the patients 
were not in remission in this cohort of RA patients in the US who were treated 
with a biologic recently; they experienced disproportionate level of disease burden. 
As the line of treatment increased, proportion of individuals achieving remission 
decreased. These observed patterns warrant further scrutiny to determine the best 
practices and improve remission rates, thereby alleviating patient burden.
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objeCtives: A common application of personalized medicine is testing for thio-
purine S-methyltransferase (TPMT) status prior to treatment with thiopurine 
drugs which are used to treat several auto-immune disorders and acute lympho-
blastic leukemia (ALL). The objective was to systematically review guidelines that 
include statements regarding TPMT testing to 1) investigate variations in testing 
and dosing recommendations and 2) appraise their quality. Methods: Citation 
databases, websites and online repositories were searched. Guidance documents 
were compared within therapeutic areas. A quality appraisal was carried out by 
three appraisers using AGREE-II. Scores were recorded for domains related to Scope 
and purpose, Stakeholder involvement, Rigor of development, Clarity of presenta-
tion, Applicability and Editorial independence. Guidance documents were scored 
and ranked according to quality. Results: A total of 20 guidelines were reviewed, 
covering inflammatory bowel disease (IBD) (n= 8), inflammatory skin disorders 
(n= 3), autoimmune hepatitis (n= 3), rheumatic disease (n= 2), ALL (n= 2) and phar-
macogenetics in general (n= 2). Six documents focused on paediatric patients. Five 
specifically recommended genotyping while four recommended phenotyping. The 
remainder included general statements. Thirteen documents included dosing rec-
ommendations based on TPMT status, with the most common recommendation 
to avoid treatment in patients with extremely low or absent TPMT activity and to 
reduce thiopurine doses in patients with intermediate TPMT activity. Five docu-
ments recommended adjustments of a typical dose for each TPMT genotype or 
phenotype. Wide variation in quality was observed across all domains. Guidance 
documents that included dosing recommendations demonstrated higher qual-
ity. ConClusions: Variations in TPMT testing recommendations reflect the need 
for clarity in the clinical validity and utility of alternative TMPT test methods. The 
variable quality among guidelines illustrated a lack of consistency and rigor in the 
methods used to develop recommendations. Interdisciplinary collaboration between 
experts in genetics, pharmacology and clinical disciplines and careful adherence to 
methods for evidence-based guideline development is warranted.
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objeCtives: To assess the impact of disease severity on duration of use of first 
biologic among patients with RA in 5EU. Methods: A multi-country multi-center 
medical chart-review study of RA patients was conducted between 3Q2011-1Q2012 
among physicians (rheumatologists:97%) in hospitals and private practices to 
collect de-identified data on patients who were recently treated with a biologic 
as part of usual care. Physicians were screened for duration of practice (3-30 
yrs) and patient volume (incl. > 2RA biologic-patients/week) and recruited from 
a large panel to be geographically representative in each country. Medical charts 
for ~10 successive patients visiting each center/practice during study-screening-
period were abstracted to collect patient diagnosis, treatment patterns/dynamics 
and disease severity/status (per physician-judgment). Kaplan-Meier (KM) analy-
sis was conducted to determine time-to-discontinuation of 1st-biologic by 50% 
of patients. Results: 4367 eligible RA patients were included in the analysis; 
mean-age:51.7yrs; female:71%(range:63%(Germany)-75%(France)). Geographic dis-
tribution of patients were – UK/France/Spain:20% each, Germany:18%, Italy:21%. 
Percentage patients currently on 1st-line-biologic:74% (range:69%(France)-
77%(Italy)), on 2nd-line-biologic:19%(19% in all countries except Spain(21%)), 
on > = 3rd-line-biologic:7%(range:4%(Italy)-12%(France)). Time between diag-
nosis & 1st-biologic:52mo(range:31mo(Spain)-57mo(UK)). Medications used 
prior to 1st-biologic were mostly Non-biological-DMARDs and corticosteroids. 
Disease-severity at diagnosis (mild:moderate:severe): overall-11%:64%:22%, 
UK-15%:57%:25%, Germany-17%:68%:13%, France-7%:63%:26%, Italy-8%:65%:25%, 
Spain-9%:70%:18%. Current disease-severity (mild:moderate:severe): over-
all-50%:41%:8%, UK-55%:30%:14%, Germany-51%:41%:8%, France-41%:48%:10%, 
Italy-48%:47%:5%, Spain-57%:38%:5%. Per KM-analysis, time-to-discontinuation 
of 1st-biologic by 50% of patients was (months):53 (UK-53/Germany-47/France-59/
Italy-57/Spain-46); KM-analysis stratified by disease-severity at initial RA-diagnosis 
revealed differences between disease-severity groups (5EU-aggregate): mild-61mo, 
moderate-56mo, severe-43mo; KM-analysis stratified by disease-severity at 1st-bio-
logic initiation also revealed distinct differences (5EU-aggregate): moderate-61mo, 
severe-45mo (mild-group had inadequate events (of discontinuation) for evalua-
tion). ConClusions: Among this large cohort of RA patients who received a bio-
logic, disease severity differed within 5EU. Time-to-discontinuation of 1st-biologic by 
50% of patients also varied across 5EU, decreasing with increasing patient severity. 
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objeCtives: To investigate the effect of CZP treatment on workplace and household 
productivity and social participation in US RA pts with and without prior anti-TNF 
exposure in the PREDICT trial (NCT01255761). Methods: Pts received CZP standard 
dosing regimen (400mg at Wks 0, 2, 4 [loading dose], then 200mg Q2W). The arthritis-
specific Work Productivity Survey (WPS; administered Q4W until Wk24, then Q8W) 
assessed the impact of CZP on workplace and household productivity, stratified by 
pts with (A) and without (B) prior anti-TNF exposure. Mean WPS responses (LOCF) 
are summarized over 52 wks Results: 733 pts were randomized; 55.5% were prior 
anti-TNF failures. At baseline (BL), 38.8% (A) and 49.4% (B) pts were employed outside 
the home. A high burden of RA on workplace and household productivity and social 
participation at BL was reported, with on average > 6 working days (A: mean 1.8 work 
days missed, 6.5 days with reduced productivity/month; B: mean 1.1 work days 
missed, 4.9 days with reduced productivity/month) and > 14 days of household work 
(A: mean 9.6 housework days missed, 7.8 days with reduced productivity/month; 
B: mean 7.5 housework days missed, 7.4 days with reduced productivity/month) 
affected per month. By Wk4, pts reported reductions in workplace absenteeism 
and presenteeism (A: mean 1.2 days missed, 3.0 days with reduced productivity/
month; B: mean 0.7 days missed, 1.9 days with reduced productivity/month), and 
improvements in household productivity (A: mean 6.2 housework days missed, 
4.8 days with reduced productivity/month; B: mean 4.4 days missed, 4.0 days with 
reduced productivity/month). Improvements continued to Wk12 and were main-
tained to Wk52. Similar improvements in social participation were reported in both 
groups. ConClusions: In RA pts initiating CZP, there were similar improvements 
between those with and without prior anti-TNF exposure in workplace, household 
productivity and social participation. These improvements were observed as early 
as Wk4 and maintained through Wk52.
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objeCtives: To describe the level of serum vitamin D (25(OH)D) inadequacy by gen-
der and race among US adults using national level data. Methods: Cross-sectional 
study was conducted using the National Health and Nutrition Examination Survey 
(NHANES) from 2001 to 2006, i.e., the latest data including serum 25(OH)D concen-
tration, including all US adults (> = 40 years). Predictive factors of serum 25(OH)D 
inadequacy (i.e., < 20 ng/ml) were evaluated using study variables including patient 
demographic, health and lifestyle factors, health care utilization, insurance cover-
age, and clinical comorbidities. All analyses were performed with SAS statistical 
software, version 9.1, at an alpha of 0.05. Results: Of 125 million adults, 37.3% 
had inadequate serum 25(OH)D levels. The inadequacy was higher in female than 
male participants (40.6% vs 33.6%: p< 0.0001, respectively). Among race/ ethnicity 
groups, the prevalence of serum 25(OH)D inadequacy was significantly higher in 
non-hispanic black populations (77.6%), hispanic populations (50.5%), and other race 
(53.2%) than non-hispanic whites (29.7%) (p< .0001). Participants who had no health 
insurance coverage was associated with the higher prevalence of serum 25(OH)D 
inadequacy (47.4% vs. 35.9%: p< 0.0001). ConClusions: A significant number of US 
adults maintain inadequate serum 25(OH)D level. The prevalence of the inadequacy 
was significantly higher in female participants and black populations as compared 
to their counterparts. Coordinated efforts through comprehensive programmatic 
approaches or improved collaboration including other health care professionals 
such as pharmacists and nutritionists can be a key element to improve vitamin D 
adequacy in US health care system.
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objeCtives: To assess the patterns of disease remission among Rheumatoid 
Arthritis (RA) patients recently treated with biologic therapies in the United States 
(US). Methods: A multi-center medical chart-review study of RA patients was 
conducted among physicians (majority: rheumatologists) in hospitals/private prac-
tices to collect de-identified data on patients who are currently on a biologic or 
recently discontinued a biologic within past 3-months. Physicians were screened 
for practice-duration and patient-volume and recruited from a large panel to be 
geographically representative of the US. Patient charts of ~10 successive patients vis-
iting each center/practice during study period were selected. Physicians abstracted 
patient diagnosis, treatment patterns/dynamics and patient symptomatology/dis-
ease status (incl. assessment of ‘disease remission’, per physician clinical judg-
ment). Results: In 4Q2011, 109 physicians abstracted 851 eligible RA patient charts; 
patient mean-age:51yrs, female:73%; 69% and 24% were on 1st line and 2nd line 
biologic respectively. Overall, 48% of patients were in remission. Remission-rate dif-
fered by biologic lines: 1st-line:51%, 2nd-line:45%, 3rd-line:26%, 4th-line:27%. Among 
